In a filing with the stock exchanges, the company informed, “Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015, we would like to inform you that a patent has been granted to the Company for an invention entitled ‘Dual Release Gastro-Resistant Composition’ for the term of 20 years from 19th November, 2022 in accordance with the provisions of the Patents Act, 1970.”
The patent, numbered 573119, was granted on October 31, 2025, as confirmed by the Patent Certificate issued by the Patent Office, Government of India. The certificate states:
“It is hereby certified that a patent has been granted to the patentee for an invention entitled DUAL RELEASE GASTRO-RESISTANT COMPOSITION as disclosed in the above mentioned application for the term of 20 years from the 19th day of November 2022 in accordance with the provisions of the Patents Act, 1970.”
Also Read: Akums unveils Rabeprazole plus Levosulpiride SR Capsules for GERD in India
Next-Generation Proton Pump Inhibitor for GERD
Akums highlighted that the patented formulation represents an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment-resistant gastroesophageal reflux disease (GERD) — one of the most prevalent digestive disorders globally.
The company explained, “GERD affects nearly 14% of the global population, with an estimated 784 million people living with the condition as of 2019. In India, recent meta-analyses estimate a pooled prevalence of 15.6%.”
GERD occurs when stomach acid repeatedly flows back into the esophagus, leading to heartburn and discomfort. PPIs such as Pantoprazole and Esomeprazole are commonly used to reduce stomach acid and promote healing of acid-related damage. However, conventional PPIs may not sustain their effect throughout the day, often causing “nocturnal acid breakthrough and incomplete symptom relief.”
Dual Release Formulation for Extended Relief
To address these challenges, Akums developed the new dual release formulation which, “releases the medicine in two phases — 50% in the duodenum and 50% in the ileum — and hence an extended absorption of drug, and hence extended duration of action.”
The company added that this dual release gastro-resistant tablet has been designed to provide, “better heartburn free days (daytime or night time), long-lasting heartburn relief, improved compliance, and enhanced quality of life with just one tablet a day.”
Akums further stated that its unique “tablet-in-tablet technology” ensures better stability, uniform drug release, and improved formulation attributes.
“This advanced, once-daily formulation has received DCGI approval and reinforces Akums’ commitment to developing innovative and patient-friendly therapies for chronic acid-related disorders,” the company noted.
The announcement, signed by Dharamvir Malik, Company Secretary & Compliance Officer, also included a copy of the official patent certificate for reference.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.